The Ultimate Pharmaceutical Stock to Buy With $1,000 Right Now

Date:

Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue growth thanks to the fact that patients need their medicines — so will continue with them no matter what the economy is doing. A top pharma stock also may have one particular star product that brings in blockbuster revenue, and this growth could drive stock performance. Finally, pharma stocks often pay dividends, an extra bonus to ensure that every year you’ll generate income from this investment — without lifting a finger.

Of course, to benefit from all of this, you’ll want to invest in these players for the long term, meaning at least five years. This offers you the opportunity to potentially score a win as revenue grows and collect passive income along the way. One pharmaceutical company in particular offers everything I mentioned above. And with $1,000, you can get in on this player that should offer you the fantastic combination of stability and growth over time. Let’s check out this ultimate pharma stock to buy now.

Are You Missing The Morning Scoop? Wake up with Breakfast news in your inbox every market day. Sign Up For Free »

Image source: Getty Images.

This particular stock has made the headlines this year as it sells one of the most sought-after products around: weight-loss drugs. In fact, this company is a leader in the market, generating double-digit revenue growth and billion-dollar revenue every quarter. I’m talking about Eli Lilly (NYSE: LLY), maker of Mounjaro and Zepbound.

Both drugs are based on the same molecule — tirzepatide — but Mounjaro is approved for type 2 diabetes, and Zepbound is approved for weight loss. Doctors have prescribed both for weight control, though, especially prior to the Zepbound approval a year ago. Mounjaro won the regulatory nod earlier, in 2022.

These drugs, known as GIP and GLP-1 receptor agonists, work by acting on hormones involved in blood sugar regulation and appetite. They’ve demonstrated excellent results in clinical trials and in the real world — and that’s helped demand to soar. In fact, demand for these weight loss drugs from Lilly and similar ones from rival Novo Nordisk surpassed supply, prompting both companies to ramp up their manufacturing capacity.

Today, Mounjaro and Zepbound both have become blockbusters, and in the most recent quarter, they generated $3.1 billion and $1.2 billion in revenue, respectively. Goldman Sachs predicts the weight loss drug market may reach $130 billion by the end of the decade, according to Bloomberg. This suggests plenty of growth may be ahead.

Share post:

Popular

More like this
Related

Where 49ers would pick in 2025 NFL Draft after loss to Dolphins

Where 49ers would pick in 2025 NFL Draft after...

Giants take sole possession of No. 1 overall pick in 2025 NFL Draft with Raiders’ win over Jaguars

With the Raiders' 19-14 win over the Jacksonville Jaguars...

Commitment to golf at Harvard a no-brainer for Mayo standout Isaac Ahn

Dec. 22—Dartmouth was knocking on Isaac Ahn's door.Columbia, too.In...

Maiocco’s Observations: Deebo resembles old self in 49ers’ loss

Maiocco's Observations: Deebo resembles old self in 49ers' loss...